iniparib Articles
Disappointments for Sanofi’s iniparib in Ph III breast cancer study and Ipsen’s Irosustat
8 June 2011
Disappointments as Actelion and GSK discontinue almorexant in sleep disorder and Sanofi’s iniparib fails in Ph III
28 January 2011
Strong cancer drug results presented by Roche, Sanofi-Aventis, Merck KGaA, Amgen and Eisai at ESMO Congress
12 October 2010
Showing 1-3 of 3 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
